Science Explorer Back to mapMap
Discussion
Topic · Economics and Econometrics

Pharmaceutical Economics and Policy

Pharmaceutical Economics and Policy is a research topic within Economics and Econometrics. Science Explorer counts 28k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the economics of pharmaceutical research and development, focusing on topics such as drug development costs, generic drugs, pharmaceutical innovation, medicine prices, patent expiry, healthcare policies, market size, availability of medicines, and generic substitution.

  • Drug Development Costs
  • Generic Drugs
  • Pharmaceutical Innovation
  • Medicine Prices
  • Patent Expiry
  • Healthcare Policies
  • Market Size
  • Availability of Medicines
  • Generic Substitution
  • Pharmaceutical Industry
Research works
28k
fractional, since 1950
In the world top 10%
2.9k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+6%
the tick is no change
Largest producer
United States
41% of the 10 largest, 2022-now
Pharmaceutical Economics and Policy

Which countries lead Pharmaceutical Economics and Policy research?

By volume, the United States and India publish the most (1.5k and 519 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.5k works
  2. 2 India 519 works
  3. 3 United Kingdom 414 works
  4. 4 China 302 works
  5. 5 France 239 works
  6. 6 Germany 178 works
  7. 7 Canada 175 works
  8. 8 Italy 167 works
  9. 9 Spain 136 works
  10. 10 Australia 127 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 40.6%India: 13.7%United Kingdom: 10.9%China: 7.9%6 others listed: 26.9%41%largest
United States1,544 · 40.6%India519 · 13.7%United Kingdom414 · 10.9%China302 · 7.9%6 others listed1,021 · 26.9%

Shares of the rows listed above, not of the whole node.

Which institutions lead Pharmaceutical Economics and Policy research?

By volume in 2022-now, Harvard University publishes the most Pharmaceutical Economics and Policy research, followed by Johns Hopkins University and University of Toronto.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 95 works
  2. 2 Johns Hopkins UniversityUnited States 35 works
  3. 3 University of TorontoCanada 28 works
  4. 4 Centre National de la Recherche ScientifiqueFrance 28 works
  5. 5 United States Food and Drug AdministrationUnited States 27 works
  6. 6 Tufts UniversityUnited States 24 works
  7. 7 University of North Carolina at Chapel HillUnited States 22 works
  8. 8 Yale UniversityUnited States 21 works
  9. 9 Peking UniversityChina 21 works
  10. 10 Pfizer (United States)United States 21 works

Who are the leading researchers in Pharmaceutical Economics and Policy?

The most-cited researchers publishing on Pharmaceutical Economics and Policy include David Moher, Theo Vos and George Davey Smith.

  1. 1 David Moher Canada 898k citations
  2. 2 Theo Vos United States 439k citations
  3. 3 George Davey Smith United Kingdom 435k citations
  4. 4 Zulfiqar Ahmed Bhutta Pakistan 371k citations
  5. 5 Ronald C. Kessler United States 360k citations
  6. 6 John J.V. McMurray United Kingdom 349k citations
  7. 7 Cyrus Cooper United Kingdom 342k citations
  8. 8 Stephan Windecker Switzerland 338k citations
  9. 9 Giuseppe Remuzzi Italy 328k citations
  10. 10 John P. A. Ioannidis United States 317k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Pharmaceutical Economics and Policy?

The most cited paper in Pharmaceutical Economics and Policy is "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS" (Paulus F. Kirchhof et al., 2016), with 6,496 citations. Next come "EQ-SD: a measure of health status from the EuroQol Group" (5,748) and "The price of innovation: new estimates of drug development costs" (4,325).

Most cited papers
#PaperReleasedCitations
1 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Paulus F. Kirchhof et al. · European Heart Journal Open access125 authors 27 Aug 2016 6,496
2 EQ-SD: a measure of health status from the EuroQol Group Rosalind Rabin, Frank de Charro · Annals of Medicine Open access 2001 5,748
3 The price of innovation: new estimates of drug development costs Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics Open access 28 Feb 2003 4,325
4 Can the pharmaceutical industry reduce attrition rates? Ismail Kola, John Richard Landis · Nature Reviews Drug Discovery 30 Jul 2004 4,181
5 How to improve R&D productivity: the pharmaceutical industry's grand challenge Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie et al. · Nature Reviews Drug Discovery Review 19 Feb 2010 3,579
All 99 most cited papers, with filters and sorting

Where is Pharmaceutical Economics and Policy research done?

The largest centres of Pharmaceutical Economics and Policy research in 2022-now are London (United Kingdom), Boston (United States), New York (United States) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Silver Spring and Sanaa.

Largest cities, 2022-now

  1. 1 LondonUnited Kingdom 162 works
  2. 2 BostonUnited States 109 works
  3. 3 New YorkUnited States 95 works
  4. 4 ParisFrance 80 works
  5. 5 Washington D.C.United States 79 works
  6. 6 BeijingChina 70 works
  7. 7 CambridgeUnited States 67 works
  8. 8 TokyoJapan 61 works
  9. 9 MoscowRussia 54 works
  10. 10 TorontoCanada 48 works

Where it is the local speciality

  1. Silver SpringUS · 26.5 works21×
  2. SanaaYE · 26.8 works20×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Pharmaceutical Economics and Policy than the world average.

See Pharmaceutical Economics and Policy on the map

Where is the best place to study Pharmaceutical Economics and Policy?

Among universities, judged by research, Harvard University, London School of Economics and Political Science and University of York score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 20.11%fractional works in this field (log) →share of work in the world top 10% →University of YorkLondon School of Eco…Harvard UniversityTufts University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 87.421.4%5.7×95 +19.2%
2London School of Economics and Political ScienceUnited Kingdom 72.523.3%16.0×20 +29.6%
3University of YorkUnited Kingdom 62.925.8%5.4×10 +51.1%
4Tufts UniversityUnited States 62.816.3%9.8×24 +43.4%
5London School of Hygiene & Tropical MedicineUnited Kingdom 61.919.4%12.1×10 +9.9%
6KU LeuvenBelgium 58.914.0%3.6×18 +34.4%
7Johns Hopkins UniversityUnited States 58.817.2%4.3×35 -0.9%
8Peking UniversityChina 57.323.6%2.0×21 +76.9%
9University College LondonUnited Kingdom 56.817.5%2.0×17 +46.7%
10King's College LondonUnited Kingdom 55.722.6%3.0×14 +29.2%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Pharmaceutical Economics and Policy, country by country

Is Pharmaceutical Economics and Policy research growing?

Output in 2022-2025 was 6% higher than in 2018-2021, peaking in 2024. The fastest-growing topics are Pharmaceutical Economics and Policy.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Pharmaceutical Economics and Policy as a percentage of every work published that year, 0.027% in 2024.

still counting0.020%0.040%Pharmaceutical Economics and Policy0.025% in 202519801990200020102020

Fractional works of Pharmaceutical Economics and Policy over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Pharmaceutical Economics and Policy10.5% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Pharmaceutical Economics and Policy. Posts are plain text and can be reported.